ISA 2024 | Safety and tolerability SGLT2 inhibitors in the treatment of cardiac amyloidosis
In this video, Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, highlights the results from his recent work exploring the safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis. In this study, SGLT2 inhibitors were given to a cohort of patients with cardiac amyloidosis, in which they were well tolerated, with few patients having to come off the medication. Since this study did not have a control group, they could not establish whether SGLT2 inhibitors benefit patients with cardiac amyloidosis, and further research is required. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Travel funds from Janssen
